or Try an Advanced Search...

    Technical Analysis for IMTX - Immatics N.V.

    Grade Last Price % Change Price Change
    D 10.96 1.39% 0.15
    IMTX closed up 1.39 percent on Friday, May 17, 2024, on 59 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    Earnings due: Jun 5
    *** please verify all earnings dates ***
    5 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Flat Up
    Historical IMTX trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    200 DMA Support Bullish 0.00%
    Crossed Above 50 DMA Bullish 0.00%
    180 Bullish Setup Bullish Swing Setup 0.00%
    Calm After Storm Range Contraction 0.00%
    Fell Below 50 DMA Bearish 1.39%
    Gapped Up Strength 1.39%
    50 DMA Support Bullish -1.08%
    Slingshot Bullish Bullish Swing Setup -1.08%
    Upper Bollinger Band Walk Strength -1.08%
    Older End-of-Day Signals for IMTX ...

       Recent Intraday Alerts

    Alert Time
    200 DMA Resistance 3 days ago
    Up 1% 3 days ago
    10 DMA Resistance 3 days ago
    Rose Above 10 DMA 3 days ago
    20 DMA Support 3 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    IMTX Chart by TradingView
    Basic chart:

    Profile

    Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Immune System Immunotherapy Cancer Treatment Treatment Of Cancer Cell Therapy Virotherapy Immunotherapies T Cell Adoptive Cell Transfer

    Is IMTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 14 Immatics reports Q1 results
    May 14 Immatics Announces First Quarter 2024 Financial Results and Business Update
    Apr 29 Immatics N.V.: An Intriguing Developmental Concern
    Apr 27 Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case
    Mar 21 Immatics reports FY results
    Mar 21 Immatics Announces Full Year 2023 Financial Results and Corporate Update
    Mar 15 With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns
    Feb 3 Immatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last year
    Feb 3 Immatics: Pioneering TCR Therapies In The Fight Against Cancer
    Jan 18 Immatics prices upsized stock offering to raise $175 million
    See more IMTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.16
    52 Week Low 7.1583
    Average Volume 484,702
    200-Day Moving Average 10.77
    50-Day Moving Average 10.92
    20-Day Moving Average 10.60
    10-Day Moving Average 10.90
    Average True Range 0.54
    RSI (14) 53.05
    ADX 21.36
    +DI 27.98
    -DI 19.63
    Chandelier Exit (Long, 3 ATRs) 10.92
    Chandelier Exit (Short, 3 ATRs) 11.30
    Upper Bollinger Bands 11.50
    Lower Bollinger Band 9.70
    Percent B (%b) 0.7
    BandWidth 17.02
    MACD Line 0.08
    MACD Signal Line 0.00
    MACD Histogram 0.081
    Fundamentals Value
    Market Cap 1.13 Billion
    Num Shares 103 Million
    EPS -1.22
    Price-to-Earnings (P/E) Ratio -8.98
    Price-to-Sales 15.41
    Price-to-Book 4.40
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.52
    Resistance 3 (R3) 11.45 11.21 11.42
    Resistance 2 (R2) 11.21 11.07 11.24 11.39
    Resistance 1 (R1) 11.08 10.98 11.15 11.15 11.36
    Pivot Point 10.84 10.84 10.87 10.87 10.84
    Support 1 (S1) 10.71 10.70 10.78 10.78 10.56
    Support 2 (S2) 10.47 10.61 10.50 10.53
    Support 3 (S3) 10.34 10.47 10.50
    Support 4 (S4) 10.41